See every side of every news story
Published loading...Updated

Foralumab Phase 2a trial starts dosing patients at Yale MS Center

Summary by Multiple Sclerosis News Today
A multicenter Phase 2a clinical trial testing Tiziana Life Sciences’  foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has dosed the first patients enrolled at Yale MS Center. The Phase 2a study (NCT06292923) is assessing the treatment’s safety and efficacy against a placebo in up to 54 patients. Patient dosing started […] The post Foralumab Phase 2a trial starts dosing patients at Yale MS Center app…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Multiple Sclerosis News Today broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.